Oppenheimer Releases a Buy Rating on Tandem Diabetes Care (TNDM)

By Jason Carr

Oppenheimer analyst Steven Lichtman assigned a Buy rating to Tandem Diabetes Care (TNDMResearch Report) today and set a price target of $120.00. The company’s shares closed last Monday at $104.99, close to its 52-week high of $116.89.

According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -1.9% and a 50.8% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tandem Diabetes Care with a $118.71 average price target.

See today’s analyst top recommended stocks >>

Based on Tandem Diabetes Care’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $109 million and GAAP net loss of $27.11 million. In comparison, last year the company earned revenue of $93.26 million and had a GAAP net loss of $1.51 million.

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TNDM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.